Free Trial

Totally (TLY) Competitors

GBX 6.58
-0.17 (-2.52%)
(As of 03:13 AM ET)

TLY vs. KNB, SBTX, BELL, OPTI, COG, ONC, VRCI, OBI, STX, and NSCI

Should you be buying Totally stock or one of its competitors? The main competitors of Totally include Kanabo Group (KNB), SkinBioTherapeutics (SBTX), Belluscura (BELL), OptiBiotix Health (OPTI), Cambridge Cognition (COG), Oncimmune (ONC), Verici Dx (VRCI), Ondine Biomedical (OBI), Shield Therapeutics (STX), and NetScientific (NSCI). These companies are all part of the "medical" sector.

Totally vs.

Totally (LON:TLY) and Kanabo Group (LON:KNB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

38.3% of Totally shares are owned by institutional investors. Comparatively, 3.8% of Kanabo Group shares are owned by institutional investors. 12.4% of Totally shares are owned by insiders. Comparatively, 45.3% of Kanabo Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Totally has higher revenue and earnings than Kanabo Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Totally£121.20M0.11£1.78MN/AN/A
Kanabo Group£1K10,751.31-£7.99M-£0.01-170.00

In the previous week, Totally had 1 more articles in the media than Kanabo Group. MarketBeat recorded 1 mentions for Totally and 0 mentions for Kanabo Group. Totally's average media sentiment score of 0.00 equaled Kanabo Group'saverage media sentiment score.

Company Overall Sentiment
Totally Neutral
Kanabo Group Neutral

Totally received 129 more outperform votes than Kanabo Group when rated by MarketBeat users.

CompanyUnderperformOutperform
TotallyOutperform Votes
129
72.47%
Underperform Votes
49
27.53%
Kanabo GroupN/AN/A

Kanabo Group has a net margin of 0.00% compared to Totally's net margin of -0.80%. Totally's return on equity of -2.72% beat Kanabo Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Totally-0.80% -2.72% 0.30%
Kanabo Group N/A -80.16%-18.89%

Totally presently has a consensus price target of GBX 30, indicating a potential upside of 355.93%. Given Totally's higher probable upside, equities analysts plainly believe Totally is more favorable than Kanabo Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Totally
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Kanabo Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Totally has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Kanabo Group has a beta of 3.15, suggesting that its stock price is 215% more volatile than the S&P 500.

Summary

Totally beats Kanabo Group on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLY vs. The Competition

MetricTotallyMedical Care Facilities IndustryMedical SectorLON Exchange
Market Cap£12.93M£2.20B£5.10B£1.42B
Dividend Yield13.16%3.67%2.80%11.83%
P/E Ratio-515.00228.99158.291,696.80
Price / Sales0.1150,970.052,530.90285,695.83
Price / Cash9.0813.9035.6432.84
Price / Book0.372.635.412.72
Net Income£1.78M£77.12M£105.56M£165.43M
7 Day Performance-15.10%0.46%-0.64%3.40%
1 Month Performance38.53%5.26%3.41%6.28%
1 Year Performance-69.04%1.94%5.74%12.88%

Totally Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KNB
Kanabo Group
0 of 5 stars
GBX 1.75
flat
N/A-37.1%£11.07M£1,000.00-175.0023Gap Up
SBTX
SkinBioTherapeutics
0 of 5 stars
GBX 8.60
flat
N/A-39.4%£17.23M£21,949.00-430.0011
BELL
Belluscura
0 of 5 stars
GBX 10.25
flat
N/A-52.8%£16.92M£1.20M-170.8324Gap Down
OPTI
OptiBiotix Health
0 of 5 stars
GBX 18
flat
N/A+85.9%£17.63M£1.26M-120.009
COG
Cambridge Cognition
0 of 5 stars
GBX 47.50
-1.0%
N/A-56.4%£16.70M£12.77M-475.0080
ONC
Oncimmune
0 of 5 stars
GBX 24.30
-2.0%
N/A-36.9%£18.02M£1.15M-303.7552Gap Up
VRCI
Verici Dx
0 of 5 stars
GBX 7.50
flat
N/A-40.7%£18.19MN/A-150.0014Negative News
OBI
Ondine Biomedical
0 of 5 stars
GBX 6.60
flat
N/A-59.2%£18.30M£856,000.00-110.00N/A
STX
Shield Therapeutics
0 of 5 stars
GBX 2
+5.3%
N/A-70.1%£15.64M£7.40M-16.6727Gap Up
NSCI
NetScientific
0 of 5 stars
GBX 64
-0.8%
N/A-1.6%£15.33M£1.38M-492.3126

Related Companies and Tools

This page (LON:TLY) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners